Suppr超能文献

疑似子痫前期患者中可溶性内皮糖蛋白与标准评估的血浆浓度比较。

Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.

机构信息

Division of Maternal Fetal Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

出版信息

PLoS One. 2012;7(10):e48259. doi: 10.1371/journal.pone.0048259. Epub 2012 Oct 26.

Abstract

BACKGROUND

The purpose of this study was to compare plasma soluble endoglin (sEng) levels with standard clinical evaluation or plasma levels of other angiogenic proteins [soluble fms-like tyrosine kinase 1 (sFlt1) and placental growth factor (PlGF)] in predicting short-term adverse maternal and perinatal outcomes in women with suspected preeclampsia presenting prior to 34 weeks.

METHODS AND FINDINGS

Data from all women presenting at <34 weeks for evaluation of preeclampsia with singleton pregnancies (July 2009-October 2010) were included in this analysis and sEng levels were measured at presentation. Data was analyzed for 170 triage encounters and presented as median {25-75(th) centile}. Thirty-three percent of patients (56 of 170) experienced an adverse outcome. sEng levels (ng/ml) were significantly elevated in patients who subsequently experienced adverse outcomes compared to those who did not (32.3 {18.1, 55.8} vs 4.8 {3.2, 8.6}, p<0.0001). At a 10% false positive rate, sEng had higher detection rates of adverse outcomes than the combination of highest systolic blood pressure, proteinuria and abnormal laboratory tests (80.4 {70.0, 90.8} vs 63.8 {51.4, 76.2}, respectively). Subjects in the highest quartile of sEng were more likely to deliver early compared to those in the lowest quartile (HR: 14.96 95% CI: 8.73-25.62, p<0.0001). Natural log transformed sEng correlated positively with log sFlt1 levels (r = 0.87) and inversely with log PlGF levels (r = -0.79) (p<0.0001 for both). Plasma sEng had comparable area under the curve for prediction of adverse outcomes as measurement of sFlt1/PlGF ratio (0.88 {0.81, 0.95} for sEng versus 0.89 {0.83, 0.95} for sFlt1/PlGF ratio, p = 0.74).

CONCLUSIONS

In women with suspected preeclampsia presenting prior to 34 weeks of gestation, sEng performs better than standard clinical evaluation in detecting adverse maternal and fetal outcomes occurring within two weeks of presentation. Soluble endoglin was strongly correlated with sFlt1 and PlGF levels, suggesting common pathogenic pathways leading to preeclampsia.

摘要

背景

本研究旨在比较疑似子痫前期孕妇在 34 周前就诊时的血浆可溶性内皮糖蛋白(sEng)水平与标准临床评估或其他血管生成蛋白(可溶性 fms 样酪氨酸激酶 1(sFlt1)和胎盘生长因子(PlGF))的血浆水平,以预测短期不良母婴围产结局。

方法与发现

纳入 2009 年 7 月至 2010 年 10 月所有因子痫前期就诊于<34 周的单胎妊娠患者的数据,并在就诊时测量 sEng 水平。分析了 170 次分诊情况,中位数{25-75 百分位数}。33%的患者(170 例中的 56 例)发生不良结局。与未发生不良结局的患者相比,随后发生不良结局的患者 sEng 水平(ng/ml)明显升高(32.3{18.1,55.8}vs 4.8{3.2,8.6},p<0.0001)。在假阳性率为 10%时,sEng 检测不良结局的检出率高于最高收缩压、蛋白尿和异常实验室检查的组合(80.4{70.0,90.8}vs 63.8{51.4,76.2},分别)。sEng 水平最高四分位的患者与最低四分位的患者相比,更早分娩的可能性更高(HR:14.96 95%CI:8.73-25.62,p<0.0001)。

sEng 的自然对数值与 log sFlt1 水平呈正相关(r=0.87),与 log PlGF 水平呈负相关(r=-0.79)(均<0.0001)。血浆 sEng 预测不良结局的曲线下面积与 sFlt1/PlGF 比值相当(sEng 为 0.88{0.81,0.95},sFlt1/PlGF 比值为 0.89{0.83,0.95},p=0.74)。

结论

在<34 周妊娠的疑似子痫前期孕妇中,sEng 检测在两周内发生的不良母婴结局的能力优于标准临床评估。可溶性内皮糖蛋白与 sFlt1 和 PlGF 水平密切相关,提示导致子痫前期的发病机制存在共同途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf83/3482204/4aa96d08cb72/pone.0048259.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验